Janus Henderson Group PLC decreased its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 13.4% in the 1st quarter, Holdings Channel reports. The firm owned 5,100,288 shares of the medical research company’s stock after selling 788,379 shares during the quarter. Janus Henderson Group PLC owned 0.05% of NeoGenomics worth $104,352,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in the business. Ruggie Capital Group grew its position in shares of NeoGenomics by 74.1% during the 4th quarter. Ruggie Capital Group now owns 2,350 shares of the medical research company’s stock worth $30,000 after buying an additional 1,000 shares during the period. CWM LLC acquired a new stake in shares of NeoGenomics during the 4th quarter worth approximately $30,000. First Quadrant L P CA acquired a new stake in shares of NeoGenomics during the 4th quarter worth approximately $65,000. Quantamental Technologies LLC acquired a new stake in shares of NeoGenomics during the 4th quarter worth approximately $76,000. Finally, Bessemer Group Inc. acquired a new stake in shares of NeoGenomics during the 4th quarter worth approximately $78,000. Hedge funds and other institutional investors own 74.71% of the company’s stock.
NASDAQ NEO opened at $23.58 on Tuesday. NeoGenomics, Inc. has a 12-month low of $10.23 and a 12-month high of $23.85. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.59 and a quick ratio of 1.46. The firm has a market capitalization of $2.22 billion, a P/E ratio of 181.38 and a beta of 0.91.
NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, April 30th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. NeoGenomics had a negative net margin of 0.14% and a positive return on equity of 3.07%. The business had revenue of $95.60 million during the quarter, compared to the consensus estimate of $89.71 million. During the same quarter last year, the firm posted $0.04 EPS. NeoGenomics’s revenue was up 50.8% compared to the same quarter last year. On average, sell-side analysts expect that NeoGenomics, Inc. will post 0.19 earnings per share for the current year.
In related news, EVP Steven C. Jones sold 14,621 shares of NeoGenomics stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $19.24, for a total value of $281,308.04. Following the completion of the sale, the executive vice president now owns 241,815 shares of the company’s stock, valued at approximately $4,652,520.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Raymond R. Hipp sold 18,889 shares of the firm’s stock in a transaction on Tuesday, February 26th. The shares were sold at an average price of $18.90, for a total value of $357,002.10. Following the transaction, the director now owns 297,580 shares in the company, valued at $5,624,262. The disclosure for this sale can be found here. In the last three months, insiders sold 445,200 shares of company stock valued at $9,162,942. 12.20% of the stock is currently owned by insiders.
Several analysts have recently commented on NEO shares. Zacks Investment Research raised shares of NeoGenomics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Tuesday, January 8th. CIBC raised shares of NeoGenomics from a “neutral” rating to an “outperform” rating and reduced their price objective for the stock from $18.00 to $15.00 in a research report on Tuesday, March 12th. BidaskClub raised shares of NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 20th. ValuEngine raised shares of NeoGenomics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 10th. Finally, Needham & Company LLC raised their price objective on shares of NeoGenomics from $19.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, March 29th. Two analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.00.
ILLEGAL ACTIVITY NOTICE: “Janus Henderson Group PLC Has $104.35 Million Holdings in NeoGenomics, Inc. (NEO)” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2019/05/07/janus-henderson-group-plc-has-104-35-million-holdings-in-neogenomics-inc-neo.html.
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Recommended Story: What is a bull market?
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.